

May 22, 2023

Kidswell Bio Corporation

Code: 4584 (Growth Market, TSE)

Masaharu Tani, President & CEO

Establishment of stable storage and transportation system of high-quality SHED
- Executed a basic outsourcing agreement to enhance the functions of S-Quatre® -
(Excerpt from Japanese version)

Tokyo, May 22, 2023 – Kidswell Bio Corporation (KWB) is delighted to announce that a basic outsourcing agreement was executed with Alfresa Corporation (Chiyoda-ku, Tokyo, Mr. Yusuke Fukujin, Representative Director & President, hereafter Alfresa) and Mitsubishi Logistics Corporation (Chuo-ku, Tokyo, Mr. Hidechika Saito, Representative Director, President, hereafter Mitsubishi Logistics) on establishment of stable storage and transportation system of high-quality SHED (Stem Cells from Human Exfoliated Deciduous teeth) with fruitful experiences, advanced technologies, and know-how in the storage and transportation of regenerative medicine products of Alfresa and Mitsubishi Logistics.

Considering the environment in which the number of companies engaged in research and development of next-generation medical care, such as regenerative medicine, is increasing, KWB believes that Alfresa and Mitsubishi Logistics are the best partners since they are the first in the industry to establish new processes and technologies that apply distribution schemes and storage of special medicine, and they have ultra-low temperature storage and transportation technologies. KWB expects to establish a stable supply system of high-quality SHED with their facilities and technologies even in the event of a natural disaster etc.

With the agreement in collaboration with the three companies, KWB will accelerate SHED R&D activities based on S-Quatre®, which will enhance its functions from donor recruiting to storage and transportation of SHED and expand SHED pipelines with several academia and companies. KWB aims to launch the first SHED regenerative medicine product by FY2030.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com